Central Nervous System Lymphoma: Approach to Diagnosis and Treatment. Review uri icon

Overview

abstract

  • Central nervous system lymphoma (CNSL) is a rare form of extranodal non-Hodgkin lymphoma. Central nervous system lymphoma can be primary (isolated to the central nervous space) or secondary in the setting of systemic disease. Treatment of CNSL has improved since the introduction of high-dose methotrexate and aggressive consolidation regimens. However, results after treatment are durable in only half of patients, and long-term survivors may experience late neurotoxicity, impacting quality of life. Given the rarity of this disease, few randomized prospective trials exist. This leaves many questions unanswered regarding optimal first-line and salvage treatments. Recent advances in the knowledge of pathophysiology of CNSL will hopefully help the development of future treatments. This review gives an overview of the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of immunocompetent patients with CNSL.

publication date

  • January 1, 2020

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor
  • Central Nervous System Neoplasms
  • Chemoradiotherapy
  • Lymphoma, Non-Hodgkin

Identity

Scopus Document Identifier

  • 85086008379

Digital Object Identifier (DOI)

  • 10.1097/PPO.0000000000000449

PubMed ID

  • 32496457

Additional Document Info

volume

  • 26

issue

  • 3